Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | HTR1D | P28221 | 7/20 | 0.54 |
| ▸ | HTR1B | P28222 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | HTR1F | P30939 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8818387 | 0.87 | APP (0.54) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL7867370 | 0.86 | APP (0.65) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL7859779 | 0.84 | APP (0.51) | APPHTR1ASLC6A4 | |
| SCHEMBL5370625 | 0.82 | CYP1A2 (0.64) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL12128907 | 0.81 | APP (0.82) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL12129631 | 0.81 | APP (0.69) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL12128922 | 0.81 | APP (0.82) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL21088561 | 0.80 | HTR1D (0.53) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL5365293 | 0.79 | HTR6 (0.56) | APPHTR1DHTR1BCYP1A2CYP3A4 | |
| SCHEMBL24693259 | 0.79 | KDM4E (0.62) | APPHTR1DHTR1BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | FILLA SANDRA A | 2007-06-14 | — | — | US | disclosed |
| US-7230011-B2 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht6 receptor | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1377580-B1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | FILLA SANDRA ANN (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1377580-A2 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002060871-A2 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | HTR6, HTR5A, TPH1 | APP 4007/4885HTR1D 13/4885HTR1B 5/4885 |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR5A, HTR7 | APP 3886/4885HTR1D 18/4885HTR1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.